{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:09:07Z","timestamp":1788952147669,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Renal cancer is estimated to have accounted for 2.4% of all incident cancer cases worldwide in 2018. Renal cell carcinoma (RCC) is the most prevalent adult renal cancer, with the clear cell subtype accounting for 75-85% of cases and displaying pronounced genetic and biological heterogeneity. In the presence of metastatic disease, approximately 80% of patients are not expected to survive beyond one year. Immune checkpoint inhibitors targeting the programed death 1 (PD-1)\/PD-L1 axis have been demonstrated to elicit durable clinical responses in patients with RCC. Subsequent therapeutic strategies for immunotherapy-na\u00efve clear cell RCC, as recommended in the NCCN Guidelines Version 1.2026, include no preferred options; other recommended regimens encompass axitinib or lenvatinib in combination with pembrolizumab, cabozantinib with or without nivolumab, everolimus, lenvatinib, and nivolumab with or without ipilimumab. Currently, published evidence supporting the use of toripalimab in combination with axitinib as the third-line treatment for recurrent RCC remains limited. Thus, we report a case of recurrent clear cell RCC in which the patient achieved an overall survival of 14 years and sustained no radiographic evidence of disease for 45 months following third-line therapy with toripalimab in combination with axitinib. Based on the findings in this case, toripalimab combined with axitinib may be an option for relapsed clear cell RCC. Nevertheless, several limitations of this case report warrant acknowledgment: The diagnosis of recurrence was established based on imaging findings rather than confirmation via repeat biopsy and histopathological evaluation. As a case report, the level of evidence remains limited, and the reliability of the conclusions requires further validation in future studies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1885805","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:17Z","timestamp":1788948737000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib"],"prefix":"10.3389","volume":"17","author":[{"given":"Ye","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pathology, Shaoxing People\u2019s Hospital, Zhejiang","place":["Shaoxing, China"]},{"name":"School of Medicine, Shaoxing University, Zhejiang","place":["Shaoxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shaoxing People\u2019s Hospital, Zhejiang","place":["Shaoxing, China"]},{"name":"School of Medicine, Shaoxing University, Zhejiang","place":["Shaoxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkui","family":"Xiong","sequence":"additional","affiliation":[{"name":"School of Medicine, Shaoxing University, Zhejiang","place":["Shaoxing, China"]},{"name":"Department of Radiation Oncology, Shaoxing Second Hospital, Zhejiang","place":["Shaoxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-021-01506-1","article-title":"Coffee consumption and risk of renal cancer: a meta-analysis of cohort evidence","volume":"33","author":"Rhee","year":"2022","journal-title":"Cancer Causes Control CCC"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21873\/invivo.13049","article-title":"An overview of epigenetics in clear cell renal cell carcinoma","volume":"37","author":"Grammatikaki","year":"2023","journal-title":"In Vivo"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189240","article-title":"Kidney cancer: from tumor biology to innovative therapeutics","volume":"1880","author":"Rinaldi","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582887","article-title":"Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3233\/cbm-2010-0195","article-title":"Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma","volume":"7","author":"Kroeze","year":"2010","journal-title":"Cancer Biomarkers Sect A Dis Markers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-024-02059-y","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-9-158","article-title":"Microvessel density and heparanase over-expression in clear cell renal cell cancer: correlations and prognostic significances","volume":"9","author":"Ren","year":"2011","journal-title":"World J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0090-4295(99)80153-8","article-title":"Microvessel density in renal cell carcinoma: lack of prognostic significance","volume":"46","author":"MacLennan","year":"1995","journal-title":"Urology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2007.05.017","article-title":"Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer","volume":"38","author":"Mertz","year":"2007","journal-title":"Hum Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj133","article-title":"Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review","volume":"17","author":"Schoffski","year":"2006","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.08.5415","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/14737140.2015.1033408","article-title":"Axitinib in metastatic renal cell carcinoma","volume":"15","author":"Albiges","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-015-0392-7","article-title":"Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis","volume":"11","author":"Iacovelli","year":"2016","journal-title":"Target Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-018-0488-3","article-title":"Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals","volume":"18","author":"Wang","year":"2018","journal-title":"Clin Exp Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1038\/s41467-021-24112-w","article-title":"Molecular determinants of response to PD-L1 blockade across tumor types","volume":"12","author":"Banchereau","year":"2021","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2225386","article-title":"First-line ICIs in renal cell carcinoma","volume":"19","author":"Fiorentino","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 updated European Association of Urology Guidelines on Renal Cell Carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care","volume":"80","author":"Bedke","year":"2021","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1\u201312","DOI":"10.1007\/s11523-025-01194-w","article-title":"Time-dependent comparative effectiveness of first-line treatment for metastatic clear cell renal cell carcinoma: a restricted mean survival time-based network meta-analysis","volume":"22","author":"Fukushima","year":"2026","journal-title":"Target Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1\u20139","DOI":"10.1136\/jitc-2023-008475","article-title":"Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial","volume":"12","author":"Huang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41392-024-01990-2","article-title":"Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study","volume":"9","author":"Gu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-025-01464-5","article-title":"Cost-effectiveness analysis of toripalimab plus axitinib for patients with advanced renal cell carcinoma in the United States","volume":"45","author":"Alfayoumi","year":"2025","journal-title":"Clin Drug Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/jca.96514","article-title":"Administering immunotherapy after anti-vascular targeted therapy improves overall survival of patients with metastatic clear cell renal cell carcinoma","volume":"15","author":"Hou","year":"2024","journal-title":"J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104630","article-title":"Optimization of immunotherapy-based combinations for metastatic renal cell carcinoma: a network meta-analysis","volume":"208","author":"Park","year":"2025","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20210527-01225","article-title":"Preliminary effects of toripalimab combined with axitinib in the treatment of advanced renal cell carcinoma","volume":"102","author":"Zhou","year":"2022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1267","article-title":"Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study","volume":"18","author":"Huang","year":"2022","journal-title":"Future Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.07.008","article-title":"Impact of first line antiangiogenic therapy duration on nivolumab outcome in metastatic renal cell carcinoma patients treated in the GETUG-AFU 26 NIVOREN","volume":"21","author":"Guilhem-Ducleon","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116397","article-title":"Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: impact on following anti-PD-1 treatments","volume":"226","author":"Fumarola","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12894-020-00618-1","article-title":"Axitinib as a third or further line of treatment in renal cancer: a single institution experience","volume":"20","author":"Tsironis","year":"2020","journal-title":"BMC Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40801-023-00415-w","article-title":"Cabozantinib and axitinib after vascular endothelial growth factor therapy in patients with advanced renal cell carcinoma: a retrospective cohort study from England","volume":"11","author":"Brown","year":"2024","journal-title":"Drugs  Real World Outcomes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.31486\/toj.18.0015","article-title":"Limitations to the therapeutic potential of tyrosine kinase inhibitors and alternative therapies for kidney cancer","volume":"19","author":"Kamli","year":"2019","journal-title":"Ochsner J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"138\u201351","DOI":"10.3390\/cancers17152420","article-title":"Predictive biomarkers for immunotherapy in endometrial carcinoma","volume":"17","author":"Pizzimenti","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1\u201313","DOI":"10.3390\/ijms25010676","article-title":"Programmed cell death ligand 1 immunohistochemical expression and cutaneous melanoma: a controversial relationship","volume":"25","author":"Fiorentino","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04354-5","article-title":"The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice","volume":"488","author":"Fiorentino","year":"2026","journal-title":"Virchows Arch"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01605-9","article-title":"Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma","volume":"25","author":"Ishihara","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15206","article-title":"Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review","volume":"30","author":"Yonese","year":"2023","journal-title":"Int J Urol Off J Japanese Urol Assoc"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1\u201316","DOI":"10.3390\/cancers12071945","article-title":"The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials","volume":"12","author":"Carretero-Gonzalez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919861905","article-title":"Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter","volume":"11","author":"Roviello","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/pin.70030","article-title":"Increased expression of AXL and c-MET in high-grade clear cell renal cell carcinoma and its association with VEGFR-TKI treatment and PD-L1 expression","volume":"75","author":"Mikami","year":"2025","journal-title":"Pathol Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.1526","article-title":"PD-L1 upregulation by the mTOR pathway in VEGFR-TKI-resistant metastatic clear cell renal cell carcinoma","volume":"55","author":"Jeong","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B48","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","article-title":"Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events","volume":"123","author":"Grunwald","year":"2020","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03315-8","article-title":"PD-1 inhibitor improves radiosensitivity by tumor vessel normalization","volume":"134","author":"Hao","year":"2026","journal-title":"Br J Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11361","DOI":"10.1038\/s41598-023-37857-9","article-title":"Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model","volume":"13","author":"Watanabe","year":"2023","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers : the \"all-around warrior\" in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1\u201322","DOI":"10.3390\/jcm15114384","article-title":"Expression of PD-L1 and PD-L2 and their association with IFN-gamma\/STAT1\/STAT3 signaling in human clear cell renal cell carcinoma (ccRCC)","volume":"15","author":"Konya","year":"2026","journal-title":"J Clin Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0329000","article-title":"Renal cancer survival in clear cell renal cancer compared to other types of tumor histology: A population-based cohort study","volume":"20","author":"Sepp","year":"2025","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1885805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:30Z","timestamp":1788948750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1885805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2026.1885805"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1885805","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1885805"}}